Cited by 234vaccines and immunoinformatics approachesSARS-CoV-2 and COVID-19 ResearchVirology and Viral Diseases

The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.

Structure-Based Vaccine Antigen Design

Open access

Graham, Barney S., Gilman, Morgan S.A., McLellan, Jason S.·2019·Annual Review of Medicine

DOI 10.1146/annurev-med-121217-094234PMC PMC6936610

Open this paper in CoChat — free account

Abstract

Enabled by new approaches for rapid identification and selection of human monoclonal antibodies, atomic-level structural information for viral surface proteins, and capacity for precision engineering of protein immunogens and self-assembling nanoparticles, a new era of antigen design and display options has evolved. While HIV-1 vaccine development has been a driving force behind these technologies and concepts, clinical proof-of-concept for structure-based vaccine design may first be achieved for respiratory syncytial virus (RSV), where conformation-dependent access to neutralization-sensitive epitopes on the fusion glycoprotein determines the capacity to induce potent neutralizing activity. Success with RSV has motivated structure-based stabilization of other class I viral fusion proteins for use as immunogens and demonstrated the importance of structural information for developing vaccines against other viral pathogens, particularly difficult targets that have resisted prior vaccine development efforts. Solving viral surface protein structures also supports rapid vaccine antigen design and application of platform manufacturing approaches for emerging pathogens.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1146/annurev-med-121217-094234

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Burden of Respiratory Syncytial Virus Infection in Young Children
Hall, C. B., Weinberg, G. A., Iwane, M. K., Blumkin, A. K., Edwards, K. M., Staat, M. A., Auinger, P., Griffin, M. R., Poehling, K. A., Erdman, D. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804877 · Cited by 2,250
RESPIRATORY SYNCYTIAL VIRUS DISEASE IN INFANTS DESPITE PRIOR ADMINISTRATION OF ANTIGENIC INACTIVATED VACCINE12
KIM, H. W., CANCHOLA, J. G., BRANDT, C. D., PYLES, G., CHANOCK, R. M., JENSEN, K., & PARROTT, R. H. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120955 · Cited by 1,981
Structure of Dengue Virus
Kuhn, R. J., Zhang, W., Rossmann, M. G., Pletnev, S. V., Corver, J., Lenches, E. M., Jones, C. T., Mukhopadhyay, S., Chipman, P. R., Strauss, E. G., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00660-8 · Cited by 1,565
Risk of Primary Infection and Reinfection With Respiratory Syncytial Virus
Glezen, W. P. (1986) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1986.02140200053026 · Cited by 1,517
The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution
Rey, F. A., Heinz, F. X., Mandl, C. W., Künz, C., & Harrison, S. C. (1995) · Nature · doi:10.1038/375291a0 · Cited by 1,439
A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins
Corti, D., Voss, J., Gamblin, S. J., Codoni, G., Macagno, A., Jarrossay, D., Vachieri, S. G., Pinna, D., Minola, A., Vanzetta, F., et al. (2011) · Science · doi:10.1126/science.1205669 · Cited by 1,203
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
McLellan, J. S., Chen, M., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. (2013) · Science · doi:10.1126/science.1243283 · Cited by 1,126
Self-citation
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707304114 · Cited by 1,073
Self-citation
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
Cunningham, A. L., Lal, H., Kovac, M., Chlibek, R., Hwang, S.-J., Díez-Domingo, J., Godeaux, O., Levin, M. J., McElhaney, J. E., Puig-Barberà, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603800 · Cited by 1,070
AN EPIDEMIOLOGIC STUDY OF ALTERED CLINICAL REACTIVITY TO RESPIRATORY SYNCYTIAL (RS) VIRUS INFECTION IN CHILDREN PREVIOUSLY VACCINATED WITH AN INACTIVATED RS VIRUS VACCINE
Kapikian, A. Z., MITCHELL, R. H., Chanock, R. M., Shvedoff, R. A., & STEWART, C. E. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120954 · Cited by 1,035

Show all 94 references

Research works printed but not linked: 5

Chanock R, 1957, Am. J. Hyg., 66, 291
Chanock R, 1957, Am. J. Hyg., 66, 281
Graham BS, 2013, Curr. Top Microbiol. Immunol., 372, 391
Glezen WP, 1986, Am. J. Dis. Child, 140, 543
Barik S, 2013, Curr. Top. Microbiol. Immunol., 372, 173

Sorted by citations

Items 101–200 of 234

A human monoclonal antibody neutralizes SARS-CoV-2 Omicron variants by targeting the upstream region of spike protein HR2 motif
Su, H., Zhang, J., Yi, Z., Khan, S. U., Peng, M., Ye, L., Bao, A., Zhang, H., Suo, G., Li, Q., et al. (2024) · hLife · doi:10.1016/j.hlife.2024.02.001 · Cited by 15
Immunoinformatic-driven design and evaluation of multi-epitope mRNA vaccine targeting HIV-1 gp120
Ahmed, M. Z., Rao, T., Mutahir, Z., Ahmed, S., Ullah, N., & Ojha, S. C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1480025 · Cited by 14
Adaptation‐Proof SARS‐CoV‐2 Vaccine Design
Vishweshwaraiah, Y. L., Hnath, B., Rackley, B., Wang, J., Gontu, A., Chandler, M. R., Afonin, K. A., Kuchipudi, S. V., Christensen, N. D., Yennawar, N. H., et al. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202206055 · Cited by 12
Gene‐encoded nanoparticle vaccine platforms for in vivo assembly of multimeric antigen to promote adaptive immunity
Tursi, N. J., Xu, Z., Kulp, D. W., & Weiner, D. B. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1880 · Cited by 13
Grand Challenge in Human/Animal Virology: Unseen, Smallest Replicative Entities Shape the Whole Globe
Adachi, A. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00431 · Cited by 13
A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice
Brandys, P., Montagutelli, X., Merenkova, I., Barut, G. T., Thiel, V., Schork, N. J., Trüeb, B. S., Conquet, L., Deng, A., Antanasijevic, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.912898 · Cited by 11
Viral Prototypes for Pandemic Preparedness: The Road Ahead
Morabito, K. M., Cassetti, M. C., DeRocco, A. J., Deschamps, A. M., & Pierson, T. C. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad267 · Cited by 14
Charge Detection Mass Spectrometry Reveals Favored Structures in the Assembly of Virus-Like Particles: Polymorphism in Norovirus GI.1
Miller, L. M., Draper, B. E., Wang, J. C., & Jarrold, M. F. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c01913 · Cited by 12
mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases
Brandi, R., Paganelli, A., D’Amelio, R., Giuliani, P., Lista, F. R., Salemi, S., & Paganelli, R. (2024) · Vaccines · doi:10.3390/vaccines12121418 · Cited by 13
Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice
Nanishi, E., Borriello, F., Seo, H., O’Meara, T. R., McGrath, M. E., Saito, Y., Chen, J., Diray‐Arce, J., Song, K., Xu, A. Z., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00610-4 · Cited by 12
Precision Vaccinology Approaches for the Development of Adjuvanted Vaccines Targeted to Distinct Vulnerable Populations
Lee, B., Nanishi, E., Levy, O., & Dowling, D. J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061766 · Cited by 14
Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform
Sa-nguanmoo, N., Namdee, K., Khongkow, M., Ruktanonchai, U., Zhao, Y., & Liang, X. (2021) · Nano Research · doi:10.1007/s12274-021-3832-y · Cited by 12
Self-Assembling E2-Based Nanoparticles Improve Vaccine Thermostability and Protective Immunity against CSFV
Song, H., Abdullah, S. W., Pei, C., Shi, X., Chen, X., Ma, Y., Yin, S., Sun, S., Huang, Y., & Guo, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010596 · Cited by 11
Experimental and molecular dynamics simulation studies on the physical properties of three HBc-VLP derivatives as nanoparticle protein vaccine candidates
Luo, H. B., Ma, Y., Bi, J., Li, Z., Wang, Y., Su, Z. G., Gerstweiler, L., Ren, Y., & Zhang, S. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.05.040 · Cited by 11
Cryo-electron microscopy in the study of virus entry and infection
Dutta, M., & Acharya, P. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1429180 · Cited by 12
RosettaHDX: Predicting antibody-antigen interaction from hydrogen-deuterium exchange mass spectrometry data
Tran, M. H., Martina, C. E., Moretti, R., Nagel, M., Schey, K. L., & Meiler, J. (2025) · Journal of Structural Biology · doi:10.1016/j.jsb.2025.108166 · Cited by 9
Microfluidics combined with electron microscopy for rapid and high-throughput mapping of antibody–viral glycoprotein complexes
Sewall, L. M., Rocha, R. D. P. F., Gibson, G., Louie, M., Xie, Z., Bangaru, S., Tran, A. S., Ozorowski, G., Mohanty, S., Beutler, N., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01411-x · Cited by 11
Design and preclinical assessment of mRNA-1345 prefusion F glycoprotein-encoding mRNA vaccine for respiratory syncytial virus
Shaw, C. A., Stewart-Jones, G. B. E., Jorquera, P. A., Narayanan, E., Elbashir, S. M., Kapłonek, P., Ma, L., Hunter, N., Hanahoe, E., Ketova, T., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127589 · Cited by 11
Materials‐based vaccines for infectious diseases
Yang, B., & Wang, H. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1824 · Cited by 10
NIgPred: Class-Specific Antibody Prediction for Linear B-Cell Epitopes Based on Heterogeneous Features and Machine-Learning Approaches
Tung, C.-H., Chang, Y.-S., Chang, K.-P., & Chu, Y.-W. (2021) · Viruses · doi:10.3390/v13081531 · Cited by 10
The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice
Hu, L., Xu, Y., Wu, L., Feng, J., Zhang, L., Tang, Y., Zhao, X., Mai, R., Chen, L., Mei, L., et al. (2022) · Viruses · doi:10.3390/v14050854 · Cited by 11
Immune Cells Activating Biotin-Decorated PLGA Protein Carrier
Hartmeier, P. R., Kosanovich, J. L., Velankar, K. Y., Armen-Luke, J., Lipp, M. A., Gawalt, E. S., Giannoukakis, N., Empey, K. M., & Meng, W. S. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00343 · Cited by 9
Immunization of broiler chickens with recombinant alpha-toxin protein for protection against necrotic enteritis
Valipouri, A. R., Rahimi, S., Karkhane, A. A., Torshizi, M. A. K., Mobarez, A. M., & Grimes, J. L. (2022) · The Journal of Applied Poultry Research · doi:10.1016/j.japr.2022.100299 · Cited by 9
Investigation of a subunit protein vaccine for HFRS based on a consensus sequence between envelope glycoproteins of HTNV and SEOV
Liu, R., Lv, Y., Sun, W., Li, M., Ge, N., Zhu, C., Ding, Y., Liu, Z., Ma, R., Huang, Y., et al. (2023) · Virus Research · doi:10.1016/j.virusres.2023.199149 · Cited by 9
A universal design of restructured dimer antigens: Development of a superior vaccine against the paramyxovirus in transgenic rice
Ma, F., Xu, Q., Wang, A., Yang, D., Li, Q., Guo, J., Zhang, L., Ou, J., Li, R., Yin, H., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305745121 · Cited by 9
Construction and Immunological Evaluation of an Adenoviral Vector-Based Vaccine Candidate for Lassa Fever
Wang, M., Li, R., Li, Y., Yu, C., Chi, X., Wu, S., Liu, S., Xu, J., & Chen, W. (2021) · Viruses · doi:10.3390/v13030484 · Cited by 9
Towards developing multistrain PEDV vaccines: Integrating basic concepts and SARS-CoV-2 pan-sarbecovirus strategies
Fragoso-Saavedra, M., & Liu, Q. (2025) · Virology · doi:10.1016/j.virol.2025.110412 · Cited by 10
Retrospective SARS-CoV-2 human antibody development trajectories are largely sparse and permissive
Kirby, M. B., Petersen, B. M., Faris, J. G., Kells, S. P., Sprenger, K. G., & Whitehead, T. A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2412787122 · Cited by 8
A hybrid polymeric system for pulmonary mRNA delivery: Advancing mucosal vaccine development
Jiang, M., Sieber‐Schäfer, F., Carneiro, S. P., Matzek, D., Nguyen, A., Porras-Gonzalez, D., Verma, A. K., Gulko, M. K., Jürgens, D. C., Burgstaller, G., et al. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100311 · Cited by 8
Zika virus-like particle vaccine fusion loop mutation increases production yield but fails to protect AG129 mice against Zika virus challenge
Thompson, D., Guenther, B., Manayani, D. J., Mendy, J., Smith, J. D., Espinosa, D. A., Harris, E., Alexander, J., Vang, L., & Morello, C. S. (2022) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0010588 · Cited by 8
Why We Need Precision Vaccinology
Plotkin, S. A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac434 · Cited by 8
Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants
Zhang, J., Xia, Y., Liu, X., & Liu, G. (2023) · Bioengineering · doi:10.3390/bioengineering10020148 · Cited by 8
The protease associated (PA) domain in ScpA from Streptococcus pyogenes plays a role in substrate recruitment
McKenna, S., Aylward, F., Miliara, X., Lau, R. J., Huemer, C. B., Giblin, S. P., Huse, K. K., Liang, M., Reeves, L., Pearson, M., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2023.140946 · Cited by 8
Respiratory syncytial virus
Muñoz, F. M., & Englund, J. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814582-1.00011-5 · Cited by 8
SARS-CoV-2 S Glycoprotein Stabilization Strategies
Pedenko, B., Sulbarán, G., Guilligay, D., Effantin, G., & Weissenhorn, W. (2023) · Viruses · doi:10.3390/v15020558 · Cited by 8
Progress in vaccine development for infectious diseases—a Keystone Symposia report
Cable, J., Graham, B. S., Koup, R. A., Seder, R. A., Karikó, K., Pardi, N., Barouch, D. H., Sharma, B., Rauch, S., Nachbagauer, R., et al. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14975 · Cited by 8
Self-citation
“Just in Time”: The Role of Cryo-Electron Microscopy in Combating Recent Pandemics
Frank, J. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00318 · Cited by 7
An explainable language model for antibody specificity prediction using curated influenza hemagglutinin antibodiesPreprint
Wang, Y., Lv, H., Lei, R., Yeung, Y.-H., Shen, I. R., Choi, D., Teo, Q. W., Tan, T. J. C., Gopal, A. B., Chen, X., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.11.557288 · Cited by 7
Chimeric Glycoprotein Nanoparticles Elicit Robust Neutralizing Antibodies Against Epstein–Barr Virus
Sun, C., Xie, C., Fang, X., Hong, D., Zhang, H., Wu, P., Liu, Y., Bu, G., Cao, D., Situ, M., et al. (2025) · Advanced Materials · doi:10.1002/adma.202507012 · Cited by 6
Rational design of next-generation filovirus vaccines combining glycoprotein stabilization and nanoparticle display with glycan modification
Lee, Y.-Z., Zhang, Y.-N., Newby, M. L., Ward, G., Gomes, K. B., Auclair, S., DesRoberts, C., Allen, J. D., Ward, A. B., Stanfield, R. L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66367-7 · Cited by 9
Integrating protein language and geometric deep learning models for enhanced vaccine antigen prediction
Zai, X., Zhao, Y., Wang, X., Leng, M., Lu, M., Yang, Y., Zhao, X., Li, R., Li, Y., Zhang, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67778-2 · Cited by 8
An oral multivalent fusion vaccine based on antigenic fragment VP56310-500 and FlaC adjuvant confers effective protection against grass carp reovirus
Tang, B. Y., Cheng, G., Lu, Y., Li, W., Xu, Y., Yang, C., Xu, Z., Kong, W., & Su, J. (2026) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2026.111145 · Cited by 6
Virus-associated ribozymes and nano carriers against COVID-19
Dönmüş, B., ÜNAL, S., Kırmızıtaş, F. C., & Laçin, N. T. (2021) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2021.1890103 · Cited by 6
Smart de novo Macromolecular Structure Modeling from Cryo-EM Maps
Si, D., Chen, J., Nakamura, A., Chang, L., & Guan, H. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.167967 · Cited by 6
Dual-role epitope on SARS-CoV-2 spike enhances and neutralizes viral entry across different variants
Ye, G., Bu, F., Pan, R., Mendoza, A., Saxena, D., Zheng, J., Perlman, S. M., Liu, B., & Li, F. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012493 · Cited by 6
Structure-function relations of the SARS-CoV-2 spike protein and impact of mutations in the variants of concern
Rey, F. A. (2021) · Comptes Rendus Biologies · doi:10.5802/crbiol.53 · Cited by 11
Native-like soluble E1E2 glycoprotein heterodimers on self-assembling protein nanoparticles for hepatitis C virus vaccine design
He, L., Lee, Y.-Z., Zhang, Y.-N., Newby, M. L., Janus, B. M., Gonzalez, F. G., Ward, G., DesRoberts, C., Hung, S.-H., Giang, E., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69418-9 · Cited by 5
Modeling the kinetics of lymph node retention and exposure of a cargo protein delivered by biotin-functionalized nanoparticles
Hartmeier, P. R., Kosanovich, J. L., Velankar, K. Y., Ostrowski, S. M., Busch, E. E., Lipp, M. A., Empey, K. M., & Meng, W. S. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.08.048 · Cited by 5
Structural mapping of polyclonal IgG responses to HA after influenza virus vaccination or infection
León, A. N., Rodriguez, A. J., Richey, S. T., de la Peña, A. T., Wolters, R. M., Jackson, A. M., Webb, K., Creech, C. B., Yoder, S. M., Mudd, P. A., et al. (2025) · mBio · doi:10.1128/mbio.02030-24 · Cited by 6
Mechanistic insights into the structure-based design of a CspZ-targeting Lyme disease vaccine
Brangulis, K., Malfetano, J., Marcinkiewicz, A. L., Wang, A., Chen, Y., Lee, J., Liu, Z., Yang, X., Strych, U., Tupiņa, D., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58182-x · Cited by 5
The Search for a Universal Influenza Vaccine: Possibilities and Limitations
Kharchenko, E. P. (2019) · Epidemiology and Vaccinal Prevention · doi:10.31631/2073-3046-2019-18-5-70-84 · Cited by 5
Broadly Neutralizing Antibodies to Highly Antigenically Variable Viruses as Templates for Vaccine Design
Pauthner, M. G., & Hangartner, L. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_221 · Cited by 5
Understanding the Structure and Function of Viral Glycosylation by Molecular Simulations: State-of-the-Art and Recent Case Studies
Fadda, E. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819475-1.00056-0 · Cited by 5
Progress in the Development of Structure-Based Vaccines
Thomas, S., & Abraham, A. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1892-9_2 · Cited by 5
Novel Strategies for Developing Next-Generation Vaccines to Combat Infectious Viral Diseases
Yuan, F., & Bluth, M. H. (2025) · Vaccines · doi:10.3390/vaccines13090979 · Cited by 5
Frontiers in Virology: An Innovative Platform for Integrative Virus Research
Adachi, A. (2021) · Frontiers in Virology · doi:10.3389/fviro.2021.665473 · Cited by 4
A bottom-up approach for the de novo design of functional proteinsPreprint
Yang, C., Sesterhenn, F., Bonet, J., van Aalen, E. A., Scheller, L., Abriata, L. A., Cramer, J., Wen, X., Rosset, S., Georgeon, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.11.988071 · Cited by 4
Spatially regulated protease activity in lymph nodes renders B cell follicles a sanctuary for retention of intact antigensPreprint
Aung, A., Cui, A., Soleimany, A. P., Bukenya, M., Lee, H., Cottrell, C. A., Silva, M., Kirkpatrick, J. D., Gregory, J. R., Amlashi, P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.15.468669 · Cited by 4
A tale of two fusion proteins: understanding the metastability of human respiratory syncytial virus and metapneumovirus and implications for rational design of uncleaved prefusion-closed trimersPreprint
Lee, Y.-Z., Han, J., Zhang, Y.-N., Ward, G., Gomes, K. B., Auclair, S., Stanfield, R. L., He, L., Wilson, I. A., & Zhu, J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.07.583986 · Cited by 4
A Perspective on Vaccinology
Chu, H. Y. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae506 · Cited by 3
Modulating Adjuvant Release Kinetics From Scaffold Vaccines to Tune Adaptive Immune Responses
Sobral, M. C., Cabizzosu, L., Kang, S. J., Feng, Z., Ijaz, H., & Mooney, D. J. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304574 · Cited by 4
Plug-and-display nanoparticle immunization of the core epitope domain induces potent neutralizing antibody and cellular immune responses against PEDV
Li, M., Chen, Y., Wang, S., Sun, X., Du, Y., Liu, S., Li, R., Chang, Z., Ding, P., & Zhang, G. (2024) · Journal of Integrative Agriculture · doi:10.1016/j.jia.2024.05.002 · Cited by 3
Beta Spike-Presenting SARS-CoV-2 Virus-like Particle Vaccine Confers Broad Protection against Other VOCs in Mice
Ullah, I., Symmes, K., Keita, K., Zhu, L., Grunst, M. W., Li, W., Mothes, W., Kumar, P., & Uchil, P. D. (2024) · Vaccines · doi:10.3390/vaccines12091007 · Cited by 3
Unveiling the properties of ascorbic acid against M. tb through in silico approach: A comparative drug-based study
Kaushik, A., Peshrana, A., Barapatre, R., Pansheriya, S., & Kaushal, R. S. (2025) · Journal of Molecular Modeling · doi:10.1007/s00894-025-06322-x · Cited by 3
Immunofocusing design of a fusion glycoprotein monomer vaccine for respiratory syncytial virus
Li, Q., Li, Z., Chen, J., He, Q., Xiao, H., Li, H., Li, H., Zhang, H., Yang, Y., Bi, R., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.07.040 · Cited by 3
Development of a rapid neutralization testing system for Rhinovirus C15 based on the enzyme-linked immunospot assay
Zhou, Z., Zhu, R., Yang, H.-W., Xu, L., Chen, H., Wu, Y., Yin, Z., Huang, Q., Zhang, D., Liu, C., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.983656 · Cited by 3
Protein Oligomer Engineering: A New Frontier for Studying Protein Structure, Function, and Toxicity
Liu, C., & Luo, J. (2023) · Angewandte Chemie · doi:10.1002/ange.202216480 · Cited by 3
Engineering a cleaved, prefusion-stabilized influenza B virus hemagglutinin by identification and locking of all six pH switches
Juraszek, J., Milder, F. J., Yu, X., Blokland, S., van Overveld, D., Abeywickrema, P. D., Tamara, S., Sharma, S. P., Rutten, L., Bakkers, M. J. G., et al. (2024) · PNAS Nexus · doi:10.1093/pnasnexus/pgae462 · Cited by 3
Entry of Enveloped Viruses into Host Cells: Membrane Fusion
Más, V., & Melero, J. A. (2024) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-65187-8_16 · Cited by 3
A Novel Peptide-Based Enzyme-Linked Immunosorbent Assay (ELISA) for Detection of Neutralizing Antibodies Against NADC30-like PRRSV GP5 Protein
Sun, S., Zhang, K., Zhang, J., Zhang, P., He, P., Deng, D., Jiang, S., Zheng, W., Chen, N., Bai, J., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062619 · Cited by 3
mRNA-based COVID-19 vaccines: a new age
Martínez-Espinosa, R. R., & Ramírez-Vélez, G. (2021) · Proceedings of Scientific Research Universidad Anáhuac Multidisciplinary Journal of Healthcare · doi:10.36105/psrua.2021v1n2.03 · Cited by 2
An adjuvanted SARS-CoV-2 RBD nanoparticle elicits neutralizing antibodies and fully protective immunity in aged micePreprint
Borriello, F., Nanishi, E., Seo, H., O’Meara, T. R., McGrath, M. E., Saito, Y., Haupt, R. E., Chen, J., Diray‐Arce, J., Song, K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.09.459664 · Cited by 3
Antibody-Antigen Epitope Mapping by X-Ray Crystallography
Manion, A., Brooks, T. M., & Brooks, C. L. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4591-8_2 · Cited by 2
Production of Clinical-Grade SARS-CoV-2 Spike Ferritin Nanoparticle Protein Immunogen by Transient Transfection
Hajduczki, A., Chang, W. C., Barrera, R. A. D. L., Wood, J. F., Chen, W.-H., Martinez, E. J., Jensen, J. L., Sankhala, R. S., Smith, C., Anderson, A., et al. (2025) · Vaccines · doi:10.3390/vaccines13101041 · Cited by 2
A point-mutated Ag85B antigen improves recombinant bacterial expression and protects mice from aerosol M. tuberculosis challenge
Hsu, W.-L., Jiao, Y., Hvasta, M. G., Tran, K. N., Troyer, B. T., Huang, W., Kuhlman, B. A., Obregón‐Henao, A., & Lovell, J. F. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128281 · Cited by 2
Global vaccine development
Kim, J. H., & Ndembi, N. (2026) · Nature Medicine · doi:10.1038/s41591-026-04384-9 · Cited by 2
Self-derived peptides from the SARS-CoV-2 spike glycoprotein disrupting shaping and stability of the homotrimer unit
Padariya, M., Daniels, A., Tait‐Burkard, C., Hupp, T. R., & Kalathiya, U. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113190 · Cited by 2
Vaccine Development: From Concept to Clinic
Prasad, A. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839162572-00001 · Cited by 2
Protein Informatics and Vaccine Development: Cancer Case Study
Verma, S. K., Masand, N., Cheke, R. S., & Patil, V. M. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666221107160636 · Cited by 2
Personalized vaccines, novel vaccination technologies, and future prospects
Vasudevan, S. S., Kandrikar, T. Y., Sayyed, A. A., Sridhar, S., Prasad, A., Khandelwal, S., Baniya, S., Miguela, C. A. C., & Gondaliya, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18564-9.00024-2 · Cited by 2
Rapid development of SARS-CoV-2 receptor binding domain-conjugated nanoparticle vaccine candidatePreprint
Kang, Y., Sun, C., Zhuang, Z., Yuan, R.-Y., Zheng, Q., Li, J., Zhou, P., Chen, X., Zhang, X., Yu, X., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.03.366138 · Cited by 2
A broadly protective CHO cell expressed recombinant spike protein subunit vaccine (IMT-CVAX) against SARS-CoV-2Preprint
Jitender, Kumar, B. V., Singh, S., Verma, G., Kumar, R., Mishra, P. M., Kumar, S., Nagaraj, S. K., Nag, J., Joy, C. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.03.534161 · Cited by 2
Rational design of next-generation filovirus vaccines through glycoprotein stabilization, nanoparticle display, and glycan modificationPreprint
Lee, Y.-Z., Zhang, Y.-N., Newby, M. L., Ward, G., Gomes, K. B., Auclair, S., DesRoberts, C., Allen, J. D., Ward, A. B., Stanfield, R. L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.02.641072 · Cited by 2
Rapid acquisition of HIV-1 neutralization breadth in a rhesus V2 apex germline antibody mouse model after a single bolus immunizationPreprint
Ghosh, A. R., Habib, R., Mishra, N., Roark, R. S., Akauliya, M., Albowaidey, A. A., Allen, J. D., Amereh, K., Avillion, G., Bottermann, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.12.659380 · Cited by 2
Multivalent Protein Nanorings for Broad and Potent SARS‐CoV‐2 Neutralization
Behbahanipour, M., Goldin, C. J., Prato, C. A., Paletta, A. L., Bárcenas, O., Navarro, S., Pujols, J., Murgida, D. H., Tribulatti, M. V., Esperante, S., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202503487 · Cited by 1
Glycan masking in immunogen design: computational and experimental methods
Araiza, G., Morel, J., Tran, M. H., Jiang, S., Murray, S. E., Miyamoto, E., Vogts, H., Brown, K. L., Meiler, J., & Martina, C. E. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1726810 · Cited by 3
Structure-based design of soluble prefusion-stabilized herpes simplex virus type 2 glycoprotein B antigens
Sponholtz, M. R., Ma, D., Ndashimye, E., Byrne, P. O., Shu, Y., Warren, C., Thambi, N., McCool, R. S., Slein, M. D., Johnson, N. V., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117936 · Cited by 1
Self-citation
S6 and S8 as the dominant neutralizing epitopes of tilapia lake virus and their potential use as vaccines
Leng, J., Yu, J., Hu, H.-H., Tu, Y.-Y., Zhu, C., Lu, Q., He, T., Lv, M.-J., & Zhu, S. (2026) · Aquaculture · doi:10.1016/j.aquaculture.2026.744065 · Cited by 1
Rational design 2.0: transitioning from static structural biology to computational prioritization and iterative vaccine optimization for RSV
韦秀龙, Chen, J., & Li, Z. Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1862216 · Cited by 1
Identification of dominant conformational epitopes from the whole structure of the proprotein convertase subtilisin/kexin type 9
Liu, C., Xu, H., Yuan, F., Chen, W., Chen, H., Sheng, L., Wu, Y., & Li, X. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.03.066 · Cited by 1
Respiratory viruses: New frontiers—a Keystone Symposia report
Cable, J., Sun, J., Cheon, I. S., Vaughan, A. E., Castro, Í. A., Stein, S. R., López, C. B., Gostic, K. M., Openshaw, P., Ellebedy, A. H., et al. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14958 · Cited by 1
Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant
Ávila‐Nieto, C., Vergara‐Alert, J., Amengual-Rigo, P., Ainsua‐Enrich, E., Brustolin, M., de la Concepción, M. L. R., Pedreño-López, N., Rodon, J., Urrea, V., Pradenas, E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1291972 · Cited by 1
Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection
Ávila‐Nieto, C., Vergara‐Alert, J., Amengual-Rigo, P., Ainsua‐Enrich, E., Brustolin, M., de la Concepción, M. L. R., Pedreño-López, N., Rodon, J., Urrea, V., Pradenas, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46714-w · Cited by 1
Individuals Infected with SARS-CoV-2 Prior to COVID-19 Vaccination Maintain Vaccine-Induced RBD-Specific Antibody Levels and Viral Neutralization Activity for One Year
McConney, C., Kenney, D., Ennis, C. S., Smith-Mahoney, E. L., Ayuso, M.-J., Zhong, J., Douam, F., Sagar, M., & Snyder-Cappione, J. E. (2025) · Viruses · doi:10.3390/v17050640 · Cited by 1
HIV Prevention in a Time of COVID-19: A Report from the HIVR4P // Virtual Conference 2021
Laher, F., Richardson, S. I., Smith, P., Sullivan, P. S., Abrahams, A. G., Asowata, O. E., Bitangumutwenzi, P., Dabee, S., Dollah, A., Fernandez, N., et al. (2021) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2021.0138 · Cited by 1
Vaccines
Baldo, B. A., & Pham, N. H. (2020) · Springer eBooks · doi:10.1007/978-3-030-51740-3_16 · Cited by 1
Nanotechnology: New frontiers in anti-HIV therapy
Jampílek, J., & Kráľová, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99596-2.00011-x · Cited by 1
Structure-Based Design of Recombinant Spike Subunit Vaccine for Coronavirus Diseases
Mahmuda, M., Jannah, S. A., Fibriani, A., Ningrum, R. A., & Wardiana, A. (2023) · International Journal on Advanced Science Engineering and Information Technology · doi:10.18517/ijaseit.13.1.16202 · Cited by 1
A mRNA vaccine encoding for a RBD 60-mer nanoparticle elicits neutralizing antibodies and protective immunity against the SARS-CoV-2 delta variant in transgenic K18-hACE2 micePreprint
Brandys, P., Montagutelli, X., Merenkova, I., Barut, G. T., Thiel, V., Schork, N. J., Trüeb, B. S., Conquet, L., Deng, A., Antanasijevic, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.21.485224 · Cited by 1
Broad neutralization of SARS-CoV-2 variants by circular mRNA producing VFLIP-X spike in micePreprint
Seephetdee, C., Bhukhai, K., Buasri, N., Leelukkanaveera, P., Lerdwattanasombat, P., Manopwisedjaroen, S., Phueakphud, N., Kuhaudomlarp, S., Olmedillas, E., Saphire, E. O., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.17.484759 · Cited by 1

Authors: Graham, B. S., Gilman, M. S. A., & McLellan, J. S.
Affiliations: National Institutes of Health (US)
The University of Texas at Austin (US)
ORCID: Graham, Barney S.
Gilman, Morgan S.A.
McLellan, Jason S.
Venue: Annual Review of Medicine
Publisher: Annual Reviews
Published: 2019-01-27
Volume: 70
Issue: 1
Pages: 91-104
ISSN: 0066-4219 (ISSN-L)
1545-326X
DOI: 10.1146/annurev-med-121217-094234
PMC: PMC6936610
OpenAlex: W2913893387
Cited by: 234
References: 94
Citations by year: 2026: 23 · 2025: 28 · 2024: 40 · 2023: 38 · 2022: 35 · 2021: 41 · 2020: 25 · 2019: 4
FWCI: 2.32
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Annual Review of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute of Allergy and Infectious Diseases (R01AI127521)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
Keywords: structure-based vaccine design, antigen design, HIV-1 vaccine, respiratory syncytial virus, neutralizing antibodies, monoclonal antibodies, nanoparticle self-assembly, viral surface proteins, class I fusion proteins, emerging pathogens
MeSH terms: Animals, Antibodies, Monoclonal, B-Lymphocytes, Humans, Respiratory Syncytial Viruses, Sensitivity and Specificity, Structure-Activity Relationship, Vaccines, Synthetic, Viral Fusion Proteins, Viral Vaccines, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Structure-Based Vaccine Antigen Design

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks